The bipartisan cochairs of the congressional psychedelics group are praising FDA’s new draft guidelines on substances such as psilocybin and MDMA.
In a statement released on Wednesday, Reps. Lou Correa, D-CA, and Jack Bergman, R-MI, who founded the Psychedelics Advancing Therapy (PATH) Caucus, praised the FDA for its “considerable work” in releasing non-binding guidelines for comments regarding the clinical studies and development of psychedelic treatments for those with mental and behavioral disorders.
The FDA noted that psilocybin (also known as MDMA) and severe depression (also known as post-traumatic disorder or PTSD) have already been designated “breakthrough therapies”.
“As the country continues to experience tragic suicide rates and opioid overdoses, which disproportionately affect our nation’s veterans, it is important that policymakers, such as those within our caucus, pursue additional practical measures–alongside relevant agencies-“to ensure that the people who could benefit the most from these potentially-lifesaving therapies get access as quickly as possible,” said Congressmen .
The released the draft guidance just days after another group of bipartisan legislators filed a bill asking the agency to do so.
Reps. Dan Crenshaw, Mariannette Miller Meeks and Ro Khanna all reacted to FDA’s move last week. They credited it with making progress that was responsive to legislation.
The FDA’s draft guidelines provide scientists with a structure to conduct research that may lead to the creation of psychedelic drugs. The public has 60 days to comment on the final guidance.
In recent years, the interest in psychedelics grew exponentially as cities and state across the nation moved to promote research and remove criminal penalties.
FDA stated that the draft guidance “describes fundamental considerations throughout drug development including trial conduct and data collection as well as subject safety, new drug application requirements, and new drug applications.”
The bipartisan bill that was filed last week asked the Secretary of Health and Human Services of the United States, acting through the FDA Commissioner, to “issue draft guidance for public comments on considerations for conduct clinical trials for psychoedelic assisted therapies, including how those requesting an investigational use exception for such clinical trial should request interactive assistance by the Food and Drug Administration.”
If passed, the FDA would have been required to release this draft guidance within 180 calendar days. The agency, however, was clearly prepared to release the draft guidance much earlier. The bill also requires FDA to publish its final guidance document 180 days after publication of the draft. This may be enough for lawmakers to still want to advance the measure.
Marijuana Moment tracks more than 1,000 cannabis and drug policy bills that have been introduced in state legislatures, and Congress. Patreon supporters who pledge at least $25/month gain access to our interactive charts, maps and hearing calendar.
Discover more about our marijuana bills tracker. Become a Patreon supporter to gain access.
—
In the FDA’s Federal Register submission, it is noted that a docket was made available to allow people to provide comments on this draft guidance.
It is timely that the move has been made, since lawmakers and health officials are interested in expanding research on psychedelics, after studies revealed their potential to treat conditions like severe depression, addiction, and post-traumatic disorder.
Marijuana Moment questioned HHS Secretary Xavier Becerra about the department’s currently thinking around psychedelics policies last month. He said he had to “defer to” the expertise of NIDA, which is also under his agency. “I want to ensure that I touch base on what they’ve done on that.”
NIDA requested research last month into the impacts of changing laws surrounding psychedelics. This included the effects of allowing controlled access to substances such as psilocybin.
NIDA announced separately in May that they are soliciting proposals for a series research initiatives to explore the use of psychedelics to treat drug abuse, and plan to fund relevant studies with $1.5 million.
FDA and FTC Issue Warning Letters Regarding ‘Copycats’ Delta-8-THC Products That Look Like Popular Food Brands, Such As Doritos
Photo elements are courtesy of carlosemmaskype, and Apollo.
The post Congressional Psychedelics Caucus Chairs Applaud FDA for Releasing Research Guidelines To Develop Novel Medicines first appeared on Marijuana Moment.
